A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)	Alexander disease, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Central Nervous System Demyelinating Diseases, Leukoencephalopathies, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, demyelinating disease, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease	Active, not recruiting	Phase 3	2026-08-21		NCT04849741

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ionis Pharmaceuticals, Inc.	22

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Amsterdam Universitair Medische Centra - Academisch Medisch Centrum	Amsterdam	Netherlands	1
Children's Hospital of Atlanta	Atlanta	United States	5
Children's Hospital of Philadelphia	Philadelphia	United States	434
Great Ormond Street Hospital For Children Nhs Foundation Trust	London	United Kingdom	23
Lucile Packard Children's Hospital Stanford	Palo Alto	United States	20
Massachusetts General Hospital	Boston	United States	1015
McGill University Health Centre	Montreal	Canada	2
Murdoch Children's Research Institute	Parkville	Australia	21
National Center of Neurology and Psychiatry	Tokyo	Japan	3
Ospedale dei Bambini Vittore Buzzi	Milan	Italy	3
Ospedale Pediatrico Bambino Gesù	Roma	Italy	4
Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center	Tel Aviv	Israel	1
University College London Hospitals NHS Foundation Trust	London	United Kingdom	4